Glaxosmithkline Biologicals Sa

Glaxosmithkline Intellectual Property Development Limited

Utrecht University

University of Utrecht

Vincent Weynants

Jan Poolman

Nathalie Durant

Isabel De Vleeschauwer

Ralph Leon Biemans

Philippe Denoel

Johannes Petrus Maria Tommassen

Carine Goraj

Christiane Feron

Nathalie Isabelle Devos

Michiel Stork

Bruce Wayne Miller

Cindy Castado

Martine Petronella Bos

David Mayhew

Ruth Tal-Singer

Ashwani Kumar Arora

Thomas Wilkinson

Catherine Cohet

Jeanne-Marie Josephine Devaster

Francois-Xavier Jacques Berthet

Jan Tommassen

Nathalie Devos

The present invention relates to immunogenic compositions, such as vaccines, comprising immunogenic polypeptides fromand, for use in methods of boosting an immune response and methods of treatment using same. More particularly, the invention relates to use of such immunogenic compositions in methods of treating or preventing exacerbation of chronic obstructive pulmonary disease.

Methods of boosting immune responses

The present invention relates to immunogenic compositions comprising an immunogenic polypeptide fromor an immunogenic fragment thereof and/or an immunogenic polypeptide fromor an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.

Immunogenic composition, use and method of treatment

Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein.

Immunogenic composition

Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.

Vaccine

The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bacterial antibodies are generated against said antigen. Methods are also provided to upregulate expression through removal of the zinc repression mechanism of the cell or promoter or through removal of zinc from the culture medium.

[object Object]

The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standardserotype A and W SBAs can be significantly improved in this regard.

Vaccine protection assay

The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtBis shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS invaccine compositions. Bleb vaccines derived from lgtBand capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis

The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and Opc, and PorA and OpA and OpC. Alternatively, or in addition, lgtBis shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS invaccine compositions. Bleb vaccines derived from lgtBand capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

Growing community of inventors

Rixensart, Belgium

Vincent Weynants